■Koh Young Technology announced on the 28th that it has shipped the brain surgery medical robot "Geniant Cranial" to the United States for the first time. The equipment shipped this time is not for simple testing but for actual surgical use and was sold after receiving 510(k) certification from the U.S. Food and Drug Administration (FDA) in January. This marks the first case heading to the U.S. medical field, showing that Koh Young's global medical device business has entered a full-scale sales phase. Koh Young is expanding its sales to local hospitals, basing itself in a medical office located in San Diego, California. The participation in major academic conferences, including the American Association of Neurological Surgeons (AANS), and continuous efforts to enhance product recognition and contact with medical professionals have led to this initial introduction.
■Dongwha Pharm announced on the 28th that it has completed construction of its new headquarters in Sunhwa-dong, Jung-gu, Seoul, where the company was founded, and has started moving in. The building is named "Building 1897" in commemoration of the founding year of Dongwha Pharm. Officially recognized as the oldest pharmaceutical company in Korea by the Korean Guinness Association in 1996, Dongwha Pharm continues the 128-year history of the national company through its return to the founding site. The new headquarters is approximately 4,800 pyeong in size and consists of 5 basement floors and 16 floors above ground. The building, which began construction on November 21, 2022, and was completed on July 15, 2025, features the Dongwha Lounge and Cafe, a large auditorium named Bodang Hall with a capacity of 260 seats for performances and seminars, and various spaces including the lobby, with floors 5 to 16 serving as office space.
■Huons announced on the 28th that it has launched "Amotalex Injection 1.5 ml," which reduces the existing 3 ml formulation of a low-dose polydeoxyribonucleotide (PDRN) injection by half. Amotalex injection is an injectable product whose main ingredient is PDRN extracted from salmon-derived deoxyribonucleic acid (DNA). Huons explained that they launched Amotalex Injection 1.5 ml to meet the market demand for low-dose products and provide patients with a more suitable treatment solution.
■GI Innovation announced on the 28th that a patent for a protein structural combination based on the next-generation allergy treatment GI-301 (ingredient name Resigercept) has been registered in the United States. This patent secures rights to the main ingredient of GI-301 itself, and along with the high-content sialic acid patent registered in the U.S. in May, it completes an intellectual property system that can protect GI-301 in terms of ingredients, quality, and quantity. The previously registered high-content sialic acid patent is a quality-centered patent based on the premise that when the sugar component "sialic acid" is present at a high level on the protein surface, it is favorable for the development of subcutaneous injection (SC) formulations due to prolonged half-life and enhanced drug stability.
■Daewoong Pharmaceutical announced on the 28th that its project to develop next-generation manufacturing process technology for biopharmaceuticals based on digital twins has been selected as a national project in the "2025 First Biohealth Research and Development Project" organized by the Ministry of Trade, Industry and Energy. Digital twins are next-generation manufacturing technologies that accurately reproduce the actual biopharmaceutical production process in a virtual environment, continuously monitoring and optimizing the process states through real-time data collection and simulation. This enables the anticipation and quick response to potential problems that may arise during the process.
■ROKIT Healthcare announced on the 28th that it has received a U.S. patent for its complex organ 3D bioprinter technology at the end of June. The company recently completed patent registrations in Korea and China for its tissue regeneration technology using a low-temperature molding method without external additives. This has been evaluated as strengthening its global technological competitiveness at the cutting-edge level in the field of AI hyper-personalized organ regeneration platforms. The U.S. patent covers 3D bioprinting technology capable of outputting five types of bioink simultaneously, laying the technical foundation for directly printing complex organs such as hearts, livers, and pancreases in the operating room.
■JEIL PHARMACEUTICAL announced on the 28th that it has officially joined the "Pharmaceutical Bio Safety and Health Association" and is strengthening its safety and health management system through regular participation in activities. The "Pharmaceutical Bio Safety and Health Association" is an autonomous body established to seek joint response strategies for industrial accident prevention and compliance with the Severe Accident Punishment Act in the pharmaceutical and bio industry. As of the second quarter of 2025, 34 pharmaceutical companies nationwide have joined, with 87 active members including associate members. By participating in this council, JEIL PHARMACEUTICAL is enhancing its practical field safety and health management capabilities through quarterly meetings and updates on the latest safety and health issues.
■Jaseng Hospital announced on the 28th that it has obtained re-certification as a continuing education provider from the Accreditation Council for Continuing Medical Education (ACCME), the only medical institution in East Asia to do so. ACCME was jointly established by seven medical-related associations in the U.S., including the American Medical Association (AMA), the Association of American Medical Colleges (AAMC), and the American Hospital Association (AHA), and it is a non-profit organization that certifies and supervises continuing medical education (CME) programs in the U.S. To maintain their medical licenses in the U.S. and worldwide, physicians must receive a specific duration of continuing education from ACCME-accredited institutions and achieve the required scores. Jaseng Hospital has been operating continuing education programs for domestic and international medical professionals since July 2019, when it received a two-year provisional certification granted to new continuing education providers by ACCME. This month, as the four-year formal certification period successfully expires, it has received re-certification from ACCME, allowing it to retain its status as a continuing education provider until July 2029.
■Coreline Soft announced on the 28th that it has completed the registration of a U.S. patent for core technology aimed at enhancing the reliability of AI technology. The newly registered patent is for a "medical artificial neural network-based medical image analysis device and method to evaluate the analysis results of medical artificial neural networks," which has been officially registered by the U.S. Patent and Trademark Office (USPTO), and the patent certificate has also been received. This technology involves a structure where another AI verifies or judges whether to accept the inference results of medical images analyzed by AI, so-called 'AI evaluating AI' auxiliary artificial neural network system.
■Onconic Therapeutics announced on the 28th that its dual-targeting cancer drug candidate Nesupaprib has obtained a use patent (for PARP inhibitor-resistant cancer treatment) in Australia. Previously, there have been clinical attempts to confirm the effectiveness of combining PARP inhibitors with other drug classes such as ATR inhibitors among ovarian cancer patients with resistance to PARP inhibitors, but it has not been confirmed whether administering another PARP inhibitor alone to the same patient has therapeutic effects. However, it has been recognized that Nesupaprib maintains therapeutic effects even when administered alone to solid tumors resistant to existing PARP inhibitors, leading to patent recognition.
■AptaBio announced on the 28th that it has submitted an Investigational New Drug (IND) application for its oral macular degeneration treatment "ABF-101" to the U.S. Food and Drug Administration (FDA). The currently used standard treatment works by inhibiting vascular endothelial growth factor (VEGF) and is administered in the form of an intravitreal injection (IVT). While the treatment effect has been proven, patients have to endure the inconvenience of regularly receiving injections in the eye. AptaBio's "ABF-101" is the first new drug candidate with a different mechanism of action from existing VEGF inhibitors, characterized by the inhibition of the oxidative enzyme NOX, blocking inflammation, fibrosis, and neovascularization simultaneously. Unlike existing treatments that require direct injections into the eye, "ABF-101" has been developed in an oral formulation, enabling non-invasive administration, and the formulation is optimized to ensure the drug reaches the posterior eye, significantly improving medication convenience and treatment durability.